CHASE JACOMINI: Open Payments
NPI 1053960385 · FRAMINGHAM, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$223 in 10 payments from 7 companies in 2025. Trend: 2023 $95 · 2024 $714 · 2025 $223
Food & beverage: $223
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Alkermes, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $15 |
Products named: CAPLYTA, COBENFY, REXULTI, Auvelity, ARISTADA, INGREZZA, LYBALVI.
Industry payments across MA — which companies pay providers there.
